Please assess the completion status of the following clinical trial:

Trial Title: Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy male or female Japanese and Caucasian volunteers ≥18 and ≤55 years of age at the screening visit.~* Japanese subjects must:~  1. Be first generation Japanese, defined as born in Japan and both biologic parents are ethnic Japanese~ 2. Have maintained a Japanese lifestyle that has not significantly changed since leaving Japan, including having access to Japanese food and adhering to a Japanese diet.~* Caucasian subjects must be Caucasian of European or Latin American descent~* Modest elevations in LDL-C (≥100 mg/dL, but \<160 mg/dL)~Key Exclusion Criteria:~* Significant concomitant illness~* Known allergy or sensitivity to monoclonal antibodies (mAbs)~* Previous exposure to anti-ANGPTL3 antibody~* Body mass index (BMI) \>35 kg/m2 at the screening visit~Note: Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Evinacumab SC or placebo SC
- Cohort 2 (Type: EXPERIMENTAL): Low dose regimen: evinacumab IV or placebo IV
- Cohort 3 (Type: EXPERIMENTAL): High dose regimen: evinacumab IV or placebo IV
- Cohort 4 (Type: EXPERIMENTAL): Evinacumab or placebo SC every week (QW) x 8 doses
- Cohort 5 (Type: EXPERIMENTAL): Evinacumab or placebo SC x 1 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).